The Massachusetts Public Health Council has voted unanimously to approve a Determination of Need for Dana-Farber Cancer Institute to build a 300-bed cancer hospital in the Longwood Medical Area. Reportedly the only hospital of its kind in the region, the new facility will function as the primary connector at the center of the clinical collaboration between Dana-Farber, Beth Israel Deaconess Medical Center and Harvard Medical Faculty Physicians.
Dana-Farber estimated the cost of the new hospital at $1.68 billion when it announced the project in September 2023. The hospital will be located on the current site of the Joslin Diabetes Center along Brookline Avenue, adjacent to both Beth Israel Deaconess and Dana-Farber Cancer Institute.
“This is an extraordinary opportunity for Boston and the Commonwealth,” said Dana-Farber president and CEO Benjamin L. Ebert, MD, PhD. “While the incidence of cancer is rising, what we do now will determine our ability to meet the pace of the disease here and across the region.”
The post New Dana-Farber Campus Wins Key Approval appeared first on Connect CRE.
